• For Institutions

    • Corporate Services
    • Developers
  • Download
  • Help
  • About

    • Company Profile
    • License & Regulatory
    • Media coverage
longbridgelongbridge
longbridgelongbridge
Products
Pricing
Markets
Global Markets
Stock Screener
Information
Insights
News
Live
Academy
All
Options & Futures
Funds
IPO Subscription
Structured Products
Investment Wiki
Affiliate Program
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List

Ascendis Pharmac(ASND.US)

Overview
News
Financials
© 2026 Longbridge|Disclaimer

Event Tracking

Dec12
Stifel Nicolaus Raises Ascendis Pharma Target Price
19:28
Dec9
Ascendis Pharma A/S's stock price falls short of earnings expectations
18:38
Nov30
Ascendis Pharma's FDA Review Extended with High Stock Returns
22:09
Nov25
Ascendis Pharma's TransCon CNP Review Period Extended by Three Months
23:16
Nov19
JPMorgan, Bank of America and Wells Fargo all assign Ascendis Pharma A/S stock a 'Buy' or 'Outperform' rating
16:59
Nov17
Ascendis Pharmaceuticals Announces Positive Phase 3 Clinical Trial Results for TransCon CNP
21:01

Schedules & Filings

Schedules
Filings
Nov12
Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 250.54 M, Net Income -71.52 M, EPS -1.1772

Aug7
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 185 M, Net Income -45.48 M, EPS -0.7523

May1
Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 109.28 M, Net Income -102.43 M, EPS -1.7066

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
INBS
9.530
+132.44%
+5.430
ANGH
3.770
+62.50%
+1.450
WTO
1.020
+61.09%
+0.387
ESHAR
0.2500
+47.06%
+0.080
NCL
0.2731
+40.77%
+0.079
FGMCR
0.5500
+33.50%
+0.138
ESHA
19.180
+33.38%
+4.800
IPEXR
0.8000
+31.97%
+0.194
RDACR
0.2400
+26.32%
+0.050
DVLT
0.6521
+26.25%
+0.136
View More